Assessing the influence of MyD88 on the TIME, our study encompassed an appraisal of the efficacy of cancer immune responses, an examination of immune cell infiltration, and a dissection of the expression profiles of immune checkpoint genes (Fig. 5). The gene discussed is MYD88; the disease is cancer.